Literature DB >> 4292871

[Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)].

W Birkmayer, M Mentasti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4292871     DOI： 10.1007/bf01217333

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


× No keyword cloud information.
  15 in total

1.  [ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Arch Psychiatr Nervenkr       Date:  1964-12-02

2.  [On the effects of I-DOPA on motor disorders in Parkinson's syndrome. An electromyographic study].

Authors:  G GERSTENBRAND; K PATEISKY
Journal:  Wien Z Nervenheilkd Grenzgeb       Date:  1962

3.  Dopamine metabolism in Parkinson's disease.

Authors:  M GREER; C M WILLIAMS
Journal:  Neurology       Date:  1963-01       Impact factor: 9.910

4.  [Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS].

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz
Journal:  Wien Klin Wochenschr       Date:  1966-06-10       Impact factor: 1.704

5.  [Experimental findings and new aspects in extrapyramidal diseases].

Authors:  W Birkmayer
Journal:  Wien Z Nervenheilkd Grenzgeb       Date:  1966

6.  Treatment of Parkinson's syndrome with L-dopa. A double blind study.

Authors:  C Fehling
Journal:  Acta Neurol Scand       Date:  1966       Impact factor: 3.209

7.  The effect of the optical isomers of alpha-methyl-p-tyrosine upon brain and heart catecholamines in the mouse.

Authors:  C C Porter; J A Totaro; A Burcin; E R Wynosky
Journal:  Biochem Pharmacol       Date:  1966-05       Impact factor: 5.858

8.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

9.  [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease].

Authors:  O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1963-05-03       Impact factor: 1.704

10.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
View more
  20 in total

Review 1.  The significance of neuronal lateralisation in Parkinson's disease.

Authors:  P Riederer; J Sian-Hülsmann
Journal:  J Neural Transm (Vienna)       Date:  2012-02-26       Impact factor: 3.575

Review 2.  [Modern treatment of parkinsonism].

Authors:  W Birkmayer; E Neumayer
Journal:  Z Neurol       Date:  1972

3.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

Review 4.  Dopamine and disease.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1970-10-17       Impact factor: 8.262

5.  L-dopa level in plasma, primary condition for the kinetic effect.

Authors:  W Birkmayer; W Danielcyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

6.  Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.

Authors:  J Constantinidis; J Siegfried; T L Frigyesi; R Tissot
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

7.  Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.

Authors:  W Birkmayer; W Danielczyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

8.  Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.

Authors:  Gulnara R Khakimova; Elena A Kozina; Valerian G Kucheryanu; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2016-05-19       Impact factor: 5.590

Review 9.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

Review 10.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.